Leerink Partnrs Issues Positive Estimate for AbbVie Earnings

AbbVie Inc. (NYSE:ABBV) – Analysts at Leerink Partnrs lifted their Q2 2025 earnings per share estimates for shares of AbbVie in a research report issued on Monday, April 28th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of $3.24 for the quarter, up from their previous forecast of $3.06. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Leerink Partnrs also issued estimates for AbbVie’s Q3 2025 earnings at $3.18 EPS, Q4 2025 earnings at $3.33 EPS, FY2026 earnings at $14.01 EPS, FY2028 earnings at $17.67 EPS and FY2029 earnings at $19.05 EPS.

Several other analysts have also recently commented on the company. Guggenheim raised their target price on AbbVie from $214.00 to $216.00 and gave the company a “buy” rating in a research report on Tuesday. Bank of America increased their price target on AbbVie from $200.00 to $223.00 and gave the company a “neutral” rating in a research note on Tuesday, March 4th. Cantor Fitzgerald initiated coverage on AbbVie in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $210.00 price target for the company. Truist Financial increased their price target on AbbVie from $211.00 to $217.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Finally, Morgan Stanley increased their price target on AbbVie from $241.00 to $250.00 and gave the company an “overweight” rating in a research note on Monday. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $211.41.

AbbVie Stock Up 0.6 %

ABBV opened at $193.55 on Wednesday. AbbVie has a 12 month low of $153.58 and a 12 month high of $218.66. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. The stock has a market cap of $342.39 billion, a P/E ratio of 80.65, a P/E/G ratio of 1.62 and a beta of 0.55. The stock’s 50 day moving average price is $196.60 and its 200 day moving average price is $187.16.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, April 25th. The company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.40 by $0.06. AbbVie had a return on equity of 296.28% and a net margin of 7.59%. The firm had revenue of $13.34 billion for the quarter, compared to analysts’ expectations of $12.91 billion. During the same period last year, the firm earned $2.31 EPS. The firm’s revenue was up 8.4% compared to the same quarter last year.

Institutional Trading of AbbVie

Hedge funds and other institutional investors have recently modified their holdings of the company. Abound Financial LLC purchased a new stake in shares of AbbVie during the first quarter worth $30,000. Fiduciary Advisors Inc. purchased a new stake in shares of AbbVie during the fourth quarter worth $29,000. EnRich Financial Partners LLC raised its holdings in AbbVie by 196.4% during the fourth quarter. EnRich Financial Partners LLC now owns 166 shares of the company’s stock valued at $29,000 after buying an additional 110 shares in the last quarter. Promus Capital LLC acquired a new stake in shares of AbbVie in the fourth quarter worth about $30,000. Finally, Bradley & Co. Private Wealth Management LLC bought a new stake in shares of AbbVie during the 4th quarter worth about $31,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Jeffrey Ryan Stewart sold 58,832 shares of the stock in a transaction on Monday, March 31st. The stock was sold at an average price of $210.08, for a total value of $12,359,426.56. Following the completion of the sale, the executive vice president now owns 53,234 shares in the company, valued at $11,183,398.72. This represents a 52.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy J. Richmond sold 29,917 shares of the stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $202.90, for a total value of $6,070,159.30. Following the sale, the executive vice president now owns 44,284 shares of the company’s stock, valued at approximately $8,985,223.60. This represents a 40.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 113,471 shares of company stock worth $23,426,451 over the last quarter. Corporate insiders own 0.25% of the company’s stock.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a $1.64 dividend. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.39%. AbbVie’s payout ratio is currently 279.15%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.